Phase 4 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have cervical cancer that has come back or spread to other parts of the body, and whose cancer continued to grow or spread during or after chemotherapy
- People whose treating doctor has decided that the drug Tivdak is an appropriate treatment option for them based on official prescribing guidelines
- People who are willing to read, understand, and sign a consent form agreeing to take part in the study
- People who are willing to attend regular clinic visits and have repeated eye check-ups as required by the study
- People who agree to use effective birth control as outlined in the official prescribing guidelines for Tivdak
Who may not be able to join:
- People who have an active eye condition or eye disease at the time of starting the study, as assessed by the study doctor
- People who have previously been treated with Tivdak
- People who have taken part in another clinical trial and received an experimental drug within the past 30 days
- People who have a medical or mental health condition — including thoughts of self-harm or suicide within the past year, or currently — or abnormal lab results that the study doctor believes could affect participation or safety (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Type, incidence and severity of ocular adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.